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We report on a patient with chronic GVHD and bronchiolitis obliterans after BMT in whom spontaneous pneumomediastinum and subcutaneous emphysema developed without clear precipitating causes.
Case report
A 42-year-old man was diagnosed with chronic phase CML in May 1995. He received hydroxyurea (average dose 2.5 g/day) for 6 months and then interferon-␣ (10 million units/day subcutaneously) with suboptimal response.
Subsequently, BMT was performed from his HLAmatched brother. Conditioning included busulfan and cyclophosphamide. Cyclosporine and prednisone were used to prevent GVHD. The patient's post-transplantation course was complicated by acute GVHD of the skin, grade II overall, with good response to high-dose steroids.
Three months after transplantation, a nonproductive cough and shortness of breath developed. Pulmonary func- ever, at dismissal, the patient required supplemental oxygen for mild hypoxia during ambulation.
Discussion
Progressive obstructive pulmonary disease (occurring in up to 17% of patients without previous evidence of airway limitation) and bronchiolitis obliterans have been reported after allogeneic BMT. 1, 2 The cause of obstructive airway disease and bronchiolitis obliterans in transplant recipients is unclear. Postulated causes include viral infection, autoimmunity, and damage to small airways.
2 Bronchiolitis obliterans is higher in BM transplant recipients with GVHD (6%) than in those without (0%).
2 The same applies for obstructive lung disease. GVHD and prolonged methotrexate treatment are risk factors.
3 Clinically, bronchiolitis obliterans and obstructive pulmonary airway disease (defined as FEV 1 /FVC Ͻ70% and FEV 1 Ͻ80% of predicted value) are usually manifested symptomatically in the first year after transplantation.
Six cases of pneumomediastinum in allogeneic BM transplant recipients have been reported. 4 All patients received TBI for conditioning; five had bilateral pneumo- temically ill with jaundice and diarrhea, and blood cultures demonstrated CMV. Our patient had not received TBI, an indication that lung injury secondary to TBI is not a prerequisite for the development of pneumomediastinum.
Busulfan, part of the conditioning regimen in our patient, has been implicated in pulmonary damage, but not always in a dose-related manner. However, if busulfan caused the patient's pulmonary process, we would have expected restrictive rather than obstructive physiology. Similarly, hydroxyurea and interferon are unlikely to have had causative roles given the normal results of pulmonary function tests at the time of transplantation.
In conclusion, spontaneous pneumomediastinum and subcutaneous emphysema can complicate bronchiolitis obliterans after allogeneic BMT, even in the absence of pneumothorax or respiratory infection. 
